These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32864677)

  • 1. Overactive bladder syndrome: Management and treatment options.
    Hutchinson A; Nesbitt A; Joshi A; Clubb A; Perera M
    Aust J Gen Pract; 2020 Sep; 49(9):593-598. PubMed ID: 32864677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The overactive bladder syndrome].
    Verjans T; Dewandre M; Keppenne V; Leruth J; Waltregny D
    Rev Med Liege; 2023 May; 78(5-6):376-380. PubMed ID: 37350218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaginal laser for overactive bladder syndrome.
    Charalampous I; Tailor VK; Digesu A
    Int Urogynecol J; 2020 Aug; 31(8):1515-1517. PubMed ID: 32399906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation enterocystoplasty in overactive bladder: is there still a role?
    Reyblat P; Ginsberg DA
    Curr Urol Rep; 2010 Nov; 11(6):432-9. PubMed ID: 20734172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2019 Sep; 11(4):177-181. PubMed ID: 30900373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Position statement: a clinical approach to the management of adult non-neurogenic overactive bladder.
    Chung E; Lee D; Gani J; Gillman M; Maher C; Brennan J; Johns Putra L; Ahmad L; Chan LL
    Med J Aust; 2018 Jan; 208(1):41-45. PubMed ID: 29320672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature.
    Kasman A; Stave C; Elliott CS
    Neurourol Urodyn; 2019 Nov; 38(8):2083-2092. PubMed ID: 31483070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of refractory overactive bladder.
    Giarenis I; Cardozo L
    Minerva Ginecol; 2013 Feb; 65(1):41-52. PubMed ID: 23412019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].
    Rechberger T; Kulik-Rechberger B; Miotła P; Wróbel A
    Ginekol Pol; 2014 Mar; 85(3):214-9. PubMed ID: 24783434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
    Yüce T; Dökmeci F; Çetinkaya ŞE
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
    Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
    Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults.
    Alhasso AA; McKinlay J; Patrick K; Stewart L
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003193. PubMed ID: 17054163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
    Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
    BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of overactive bladder therapy: alternative to antimuscarinic agents.
    Lazzeri M; Spinelli M
    Int Braz J Urol; 2006; 32(6):620-30. PubMed ID: 17201939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of EMG biofeedback assisted pelvic floor muscle therapy on symptoms of the overactive bladder syndrome in women: A randomized controlled trial.
    Voorham JC; De Wachter S; Van den Bos TWL; Putter H; Lycklama À Nijeholt GA; Voorham-van der Zalm PJ
    Neurourol Urodyn; 2017 Sep; 36(7):1796-1803. PubMed ID: 27869312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonantimuscarinic treatment for overactive bladder: a systematic review.
    Olivera CK; Meriwether K; El-Nashar S; Grimes CL; Chen CC; Orejuela F; Antosh D; Gleason J; Kim-Fine S; Wheeler T; McFadden B; Balk EM; Murphy M;
    Am J Obstet Gynecol; 2016 Jul; 215(1):34-57. PubMed ID: 26851599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.